G. Baulier1, N. Issa2, F. Gabriel3, I. Accoceberry4, F. Camou5, P. Duffau6
2018 Vol.36, N°3 - PI 0490, PF 0493
Guidelines for preventing Pneumocystis pneumonia (PCP) in HIV patients are based on CD4 below 200/mm3. Such cut-off value is suggested to guide prophylaxis in non-HIV conditions (NHIV) especially in autoimmune and inflammatory diseases (AD). We aimed to determine if CD4 could be used to guide PCP prophylaxis in AD.
CD4 and lymphocyte-count were retrospectively studied in patients diagnosed with PCP between January 2013 and February 2016.
129 patients were included. The median CD4-count was 302/mm3 in AD, which was significantly higher than in HIV patients (19/mm3; p<0.0001). Fifty percent (n=10) of AD patients had CD4 counts greater than 300/mm3.
Prophylaxis for PCP cannot rely solely on CD4-count in NHIV patients especially in AD.
PMID: 29533748 [PubMed]
Received: 29/07/2017 - Accepted : 04/12/2017 - In Press: 26/02/2018 - Published: 17/05/2018